• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Its New Nutrition Alliance For Sleep Disorders

    Simply Wall St·03/27/2026 05:10:30
    Listen to the news

    Why the new nutrition alliance matters for Jazz Pharmaceuticals (JAZZ)

    The American Nutrition Association’s new initiative with Jazz Pharmaceuticals (JAZZ) focuses on evidence-based nutritional education for people with narcolepsy or idiopathic hypersomnia. It highlights cardiovascular and cardiometabolic risk management as a key theme for the company’s sleep portfolio.

    See our latest analysis for Jazz Pharmaceuticals.

    The recent nutrition alliance arrives alongside a 30 day share price return of 8.81% and a 90 day share price return of 10.95%. The 1 year total shareholder return of 49.64% points to momentum that has been building rather than fading.

    If this kind of health focused theme has your attention, it could be a good moment to widen your watchlist and check out 36 healthcare AI stocks

    With Jazz trading at US$189.15, carrying an intrinsic discount flag and an 18% gap to its consensus price target, the key question is whether this reflects mispricing today or the market calmly incorporating expectations about future growth.

    Most Popular Narrative: 17.4% Undervalued

    Vestra’s narrative points to a fair value of $228.96 for Jazz Pharmaceuticals versus the latest close at $189.15, indicating a clear valuation gap driven by its view on the future mix of sleep, epilepsy, and oncology cash flows.

    Using my specific fair value method, I apply a 13.5x Forward P/E multiple to the 2026 adjusted EPS guidance of $16.96 to reflect the successful "de-risking" of the oncology pipeline. Based on this approach, the valuation for JAZZ in USD is:

    I arrived at this fair value of $228.96 USD by analyzing the 5% year-over-year revenue growth and weighting the record $4.3 billion in 2025 revenue against the company's 92% gross profit margins. This fair value calculation highlights a 20.5% discount to its estimated intrinsic value at the current $182.32 price, framing JAZZ as a "Value-Growth" hybrid.

    Read the complete narrative.

    Curious what turns Jazz into a rare mix of value and growth in this narrative? The answer lies in a handful of key revenue and margin assumptions that reshape how its sleep and oncology segments contribute to future earnings.

    Result: Fair Value of $228.96 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this hinges on regulatory timelines and execution, and any setback in Ziihera approvals or pressure from oxybate generics could quickly challenge the value growth story.

    Find out about the key risks to this Jazz Pharmaceuticals narrative.

    Next Steps

    With mixed signals across growth, valuation, and execution risk, this is a moment to review the data yourself and decide quickly where you stand using the 3 key rewards and 2 important warning signs

    Looking for more investment ideas?

    If Jazz has sharpened your focus, do not stop here. Use the Simply Wall St screener to spot other opportunities that could fit your style before they move.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.